MADISON, Wis.–Promega Corporation announces the recent purchase of Turner BioSystems Inc. to grow their mutual interest in offering high quality integrated systems (optimized instrument with reagents) to life scientists in research, drug discovery and clinical diagnostics. This latest Promega expansion continues the existing synergies between the two companies. Together they have delivered integrated bioluminescent systems with Turner’s luminometers and world-class bioluminescent technologies from Promega.

“This is a natural next move for Turner,” explains Turner President Mike Molkelke. “Over the years, innovating with Promega has created productive instrument/reagent systems that scientists highly value. Both companies are eager to optimize this total systems approach for the bench top.”

“The Turner quality and our long standing relationship make this a great enhancement for all of our customers,” says Promega CEO Bill Linton. “Scientists value quality integrated systems because it frees them up to focus on the other demands in their lab. This purchase allows us to offer these systems for more applications.”

Turner and Promega have worked together in offering the Glomax® Luminometer line that is optimized for Promega bioluminescent assays. Turner offers microplate and single tube reader luminometers, fluorometers, photometers and multimode instruments for life science labs. Turner will continue its operations out of Sunnyvale, CA.

About Promega

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 14 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.